CEO of Ligand Pharmaceuticals Inc (LGND, Financial) John L Higgins bought 2,500 shares of LGND on 03/13/2019 at an average price of $114.29 a share. The total cost of this purchase was $285,725.
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand Pharmaceuticals Inc has a market cap of $2.39 billion; its shares were traded at around $116.93 with a P/E ratio of 20.81 and P/S ratio of 11.23. Ligand Pharmaceuticals Inc had annual average EBITDA growth of 59.40% over the past five years.
CEO Recent Trades:
- CEO John L Higgins bought 2,500 shares of LGND stock on 03/13/2019 at the average price of $114.29. The price of the stock has increased by 2.31% since.
Directors and Officers Recent Trades:
- Director Jason Aryeh bought 202 shares of LGND stock on 03/13/2019 at the average price of $112.51. The price of the stock has increased by 3.93% since.
For the complete insider trading history of LGND, click here
.
